Updated information and services can be found at: (5)(q31), 29, 211, 212, 213, 216, 219, 14mar [21] .
The patient did not reached hematologic response with either idarubicin/AraC (3/7) or FLAG-idarubicin schedules. Another bone marrow aspirate performed 6 weeks after the latter chemotherapy showed 12% myeloblasts. In addition, a number of hypergranular giant multilobated cells were observed (panel A). Immunocytochemistry stains (alkaline phosphatase anti-alkaline phosphatase) with CD117 (panel B) and CD25 (panel C) were positive, but CD2 was negative. Immunostain with tryptase was positive (panel D). Sanger sequencing of c-kit exons 8 and 17 ruled out mutations. We herein show atypical mastocytic cells in the setting of an evolved acute myeloid leukemia, although not fulfilling the criteria for myelomastocytic leukemia. For personal use only. on April 10, 2014. by guest bloodjournal.hematologylibrary.org From
